AbCellera Presents Data on T Cell Engager Platform at AACR 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL #AACR22--AbCellera (Nasdaq: ABCL), a technology company focused on next-generation antibody discovery, today announced the release of data on its new T cell engager platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting. AbCellera’s pos...

Related Keywords

United States ,United Kingdom ,Vancouver ,British Columbia ,Canada ,American ,British ,Jessica Yingling ,Bo Barnhart ,Neil Berkley ,Bryan Boc Barnhart ,Exchange Commission ,American Association For Cancer Research ,Abcellera Biologics Inc ,Vp Translational Research ,Translational Research At Abcellera ,Business Development ,American Association ,Cancer Research ,Translational Research ,Chief Business ,Immune Therapies ,Private Securities Litigation Reform Act ,Financial Condition ,Abcellera Biologics ,Melanie Solomon ,